Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

NCT03153319 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Mucopolysaccharidosis I
Mucopolysaccharidosis II
Mucopolysaccharidosis VI

Interventions

DRUG: Adalimumab Injection [Humira]
DRUG: Saline Solution for Injection

Sponsor

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Collaborators

[object Object]